Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$0.96
$0.010.82%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 926.53M | 957.40M | 987.57M | 1.02B | 987.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 926.53M | 957.40M | 987.57M | 1.02B | 987.80M |
| Cost of Revenue | 339.89M | 349.98M | 359.59M | 365.22M | 359.92M |
| Gross Profit | 586.64M | 607.42M | 627.97M | 653.88M | 627.88M |
| SG&A Expenses | 397.05M | 407.64M | 422.96M | 445.45M | 420.56M |
| Depreciation & Amortization | -3.91M | -3.91M | -3.91M | -3.91M | -- |
| Other Operating Expenses | -5.39M | -2.95M | -1.94M | -1.99M | 3.14M |
| Total Operating Expenses | 727.63M | 750.76M | 776.71M | 804.77M | 783.62M |
| Operating Income | 198.90M | 206.64M | 210.86M | 214.33M | 204.18M |
| Income Before Tax | 125.37M | 142.05M | 162.41M | 162.07M | 138.28M |
| Income Tax Expenses | 38.14M | 43.23M | 45.12M | 43.75M | 44.73M |
| Earnings from Continuing Operations | 87.22 | 98.83 | 117.29 | 118.32 | 93.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -3.53M | -3.53M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.22M | 98.83M | 117.29M | 114.79M | 90.01M |
| EBIT | 198.90M | 206.64M | 210.86M | 214.33M | 204.18M |
| EBITDA | 219.52M | 226.83M | 229.80M | 233.82M | 219.75M |
| EPS Basic | 0.09 | 0.10 | 0.12 | 0.12 | 0.10 |
| Normalized Basic EPS | 0.08 | 0.09 | 0.11 | 0.11 | 0.09 |
| EPS Diluted | 0.09 | 0.10 | 0.12 | 0.12 | 0.10 |
| Normalized Diluted EPS | 0.08 | 0.09 | 0.11 | 0.11 | 0.09 |
| Average Basic Shares Outstanding | 3.94B | 3.89B | 3.85B | 3.80B | 3.76B |
| Average Diluted Shares Outstanding | 3.94B | 3.89B | 3.85B | 3.80B | 3.76B |
| Dividend Per Share | 0.06 | 0.05 | 0.04 | 0.04 | 0.02 |
| Payout Ratio | 45.51% | 29.39% | 35.07% | 37.34% | 49.68% |